Dr Faro,among others, addressed that, but i understand what you mean. Since biotech is outside my comfort realm,i've wondered if mits could expalin the practical advantages of the n-assay perhaps in a way not explained before,or anything else relatable to the non science person,since he works in that environment.
It imo has more to do w established relationships,as we've discussed before. In the usa big pharma controls tech used due to those established relationships. For a practical example of how those relationships work see recent movies that address this issue.
Its hard for small companies to break into those relationships to offer something better,even for something as simple as the flat pack petri plates,as we've seen.
NNLX has tried to break into those relationships w the help of the govt, africa missions-bill gates foundations etc but has not gotten the breakthrough push they were hoping for.
big pharma has the power which makes it difficult for nnlx to negotiate anything without giving away the store(the company)-a trap many startups fall into
I've talked about this in much greater length many times many times.
Since somebody posted the nih application process -thank you whoever did that -was that you- i cant see the board while formulating this post- you can see how difficult the biotech grant application process is.
At least re the nih grant the big southern california based pharma co will be doing the application w the aid of their high paid grantwriter,which increases the chances of success.
said pharma doesnt need the grant - they are just working the system to increase their profit margin- the only thing most big businesses care about,so even if that app doesnt succeed the s cal pharma could easily pay for the study -which is after all at the s calif pharma's behest
so its a matter of INERTIA,money over all common sense,the stupidity of humans etc
humans respond to needs in knee jerk reactions -but that requires a catalyst to break through established relationships and norms
one such catalyst i've discussed before hits big co's where it hurts -their money clip.
If a technology is available that makes the critical difference between life and death eventually some hospital or other provider is going to be sued because that tech was not used.
Bu that approach - to be sucessful -requires that some decent sized providers be using that tech - so that it can be called a best practices methodology- but that takes us back to the beginning -the problem of breaking into relationships sufficient to get the tech into some decent sized providers
you probably have to start w some small providers and even discount the cost to get the ball rolling but nnlx cant afford to sell tech at less than cost
it all comes down to money-the lack of - to get things rolling- as mentioned-in the absence of money nnlx has tried to use the govt and africa etc projects to leverage-but didnt get the leverage ,movement they hoped for
all it would take is for somebody of means w enough foresight /prescience to understand the future benefits of nnlx tech to get things rolling but such people are extremely rare
licensing or sale of the petri plate tech in europe is still very possible-
but again as somebody who spent 17 yrs negotiating,negotiating in a world where EVERYBODY wants a supersized piece of the pie is a long drawn out process,which i've detailed at great length before.
you can see why the vast majority of startups fail-many never even achieve revenue let alone net revenue-nnlx is working on the net revenue equation-cost cutting to the bone so they dont end up in the great heap of failed enterprises-avoiding he traps of hostile takeovers and poisonous financing
bio tech is a tough startup business,probably taking longer than any other kind of startup if the startup doesnt have an independently wealthy sponsor.
we all want more info but nnlx apparently cant afford the fees necessary to potentially dramatically increase the shareholder base and draconian nda agreements block much of what they might want to tell us
so we swim while nnlx edges closer to net revenue- a process nnlx recognized would take too long which is why they made the potentially game changing announced july 2017? decision to license or sell petri patents in certain geographic markets
so we remain at the whim of those things which could lead to a breakthrough for nnlx- we dont know when
It imo has more to do w established relationships,as we've discussed before. In the usa big pharma controls tech used due to those established relationships. For a practical example of how those relationships work see recent movies that address this issue.
Its hard for small companies to break into those relationships to offer something better,even for something as simple as the flat pack petri plates,as we've seen.
NNLX has tried to break into those relationships w the help of the govt, africa missions-bill gates foundations etc but has not gotten the breakthrough push they were hoping for.
big pharma has the power which makes it difficult for nnlx to negotiate anything without giving away the store(the company)-a trap many startups fall into
I've talked about this in much greater length many times many times.
Since somebody posted the nih application process -thank you whoever did that -was that you- i cant see the board while formulating this post- you can see how difficult the biotech grant application process is.
At least re the nih grant the big southern california based pharma co will be doing the application w the aid of their high paid grantwriter,which increases the chances of success.
said pharma doesnt need the grant - they are just working the system to increase their profit margin- the only thing most big businesses care about,so even if that app doesnt succeed the s cal pharma could easily pay for the study -which is after all at the s calif pharma's behest
so its a matter of INERTIA,money over all common sense,the stupidity of humans etc
humans respond to needs in knee jerk reactions -but that requires a catalyst to break through established relationships and norms
one such catalyst i've discussed before hits big co's where it hurts -their money clip.
If a technology is available that makes the critical difference between life and death eventually some hospital or other provider is going to be sued because that tech was not used.
Bu that approach - to be sucessful -requires that some decent sized providers be using that tech - so that it can be called a best practices methodology- but that takes us back to the beginning -the problem of breaking into relationships sufficient to get the tech into some decent sized providers
you probably have to start w some small providers and even discount the cost to get the ball rolling but nnlx cant afford to sell tech at less than cost
it all comes down to money-the lack of - to get things rolling- as mentioned-in the absence of money nnlx has tried to use the govt and africa etc projects to leverage-but didnt get the leverage ,movement they hoped for
all it would take is for somebody of means w enough foresight /prescience to understand the future benefits of nnlx tech to get things rolling but such people are extremely rare
licensing or sale of the petri plate tech in europe is still very possible-
but again as somebody who spent 17 yrs negotiating,negotiating in a world where EVERYBODY wants a supersized piece of the pie is a long drawn out process,which i've detailed at great length before.
you can see why the vast majority of startups fail-many never even achieve revenue let alone net revenue-nnlx is working on the net revenue equation-cost cutting to the bone so they dont end up in the great heap of failed enterprises-avoiding he traps of hostile takeovers and poisonous financing
bio tech is a tough startup business,probably taking longer than any other kind of startup if the startup doesnt have an independently wealthy sponsor.
we all want more info but nnlx apparently cant afford the fees necessary to potentially dramatically increase the shareholder base and draconian nda agreements block much of what they might want to tell us
so we swim while nnlx edges closer to net revenue- a process nnlx recognized would take too long which is why they made the potentially game changing announced july 2017? decision to license or sell petri patents in certain geographic markets
so we remain at the whim of those things which could lead to a breakthrough for nnlx- we dont know when
2
1
